Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV002156729 | SCV002324470 | likely benign | not provided | 2023-09-03 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002551294 | SCV003609476 | uncertain significance | Inborn genetic diseases | 2021-10-22 | criteria provided, single submitter | clinical testing | The c.4117C>G (p.P1373A) alteration is located in exon 16 (coding exon 16) of the SPEG gene. This alteration results from a C to G substitution at nucleotide position 4117, causing the proline (P) at amino acid position 1373 to be replaced by an alanine (A). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Revvity Omics, |
RCV003138068 | SCV003820019 | uncertain significance | Myopathy, centronuclear, 5 | 2019-06-13 | criteria provided, single submitter | clinical testing | |
Breakthrough Genomics, |
RCV002156729 | SCV005258906 | likely benign | not provided | criteria provided, single submitter | not provided |